FDA Approves Label Update for Kite's Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma 06 February
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026 27 January
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer 21 January
